151 related articles for article (PubMed ID: 37111288)
1. Core Structure-Activity Relationship Studies of 5,7,20-
Wu S; Chen G; Chen EY; Farshidpour LS; Zhang Q; Wang G; Chen QH
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111288
[TBL] [Abstract][Full Text] [Related]
2. 3-
Wu S; Chen G; Zhang Q; Wang G; Chen QH
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770829
[TBL] [Abstract][Full Text] [Related]
3. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.
Davis-Searles PR; Nakanishi Y; Kim NC; Graf TN; Oberlies NH; Wani MC; Wall ME; Agarwal R; Kroll DJ
Cancer Res; 2005 May; 65(10):4448-57. PubMed ID: 15899838
[TBL] [Abstract][Full Text] [Related]
4.
Vue B; Zhang S; Vignau A; Chen G; Zhang X; Diaz W; Zhang Q; Zheng S; Wang G; Chen QH
Molecules; 2018 Nov; 23(12):. PubMed ID: 30501133
[TBL] [Abstract][Full Text] [Related]
5. Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.
Vue B; Zhang S; Zhang X; Parisis K; Zhang Q; Zheng S; Wang G; Chen QH
Eur J Med Chem; 2016 Feb; 109():36-46. PubMed ID: 26748997
[TBL] [Abstract][Full Text] [Related]
6. Tricyclic Diterpenoids Selectively Suppress Androgen Receptor-Positive Prostate Cancer Cells.
Sekhon I; Chen G; Piri K; Shinkawa S; Ashong D; Zhang Q; Wang G; Chen QH
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375297
[TBL] [Abstract][Full Text] [Related]
7. Anti-cancer efficacy of silybin derivatives -- a structure-activity relationship.
Agarwal C; Wadhwa R; Deep G; Biedermann D; Gažák R; Křen V; Agarwal R
PLoS One; 2013; 8(3):e60074. PubMed ID: 23555889
[TBL] [Abstract][Full Text] [Related]
8. Silychristin: Skeletal Alterations and Biological Activities.
Biedermann D; Buchta M; Holečková V; Sedlák D; Valentová K; Cvačka J; Bednárová L; Křenková A; Kuzma M; Škuta C; Peikerová Ž; Bartůněk P; Křen V
J Nat Prod; 2016 Dec; 79(12):3086-3092. PubMed ID: 28006905
[TBL] [Abstract][Full Text] [Related]
9. Enhanced bioactivity of silybin B methylation products.
Sy-Cordero AA; Graf TN; Runyon SP; Wani MC; Kroll DJ; Agarwal R; Brantley SJ; Paine MF; Polyak SJ; Oberlies NH
Bioorg Med Chem; 2013 Feb; 21(3):742-7. PubMed ID: 23260576
[TBL] [Abstract][Full Text] [Related]
10. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer.
Flaig TW; Glodé M; Gustafson D; van Bokhoven A; Tao Y; Wilson S; Su LJ; Li Y; Harrison G; Agarwal R; Crawford ED; Lucia MS; Pollak M
Prostate; 2010 Jun; 70(8):848-55. PubMed ID: 20127732
[TBL] [Abstract][Full Text] [Related]
11. Silibinin phosphodiester glyco-conjugates: Synthesis, redox behaviour and biological investigations.
Romanucci V; Agarwal C; Agarwal R; Pannecouque C; Iuliano M; De Tommaso G; Caruso T; Di Fabio G; Zarrelli A
Bioorg Chem; 2018 Apr; 77():349-359. PubMed ID: 29421711
[TBL] [Abstract][Full Text] [Related]
12. A New Class of Synthetic Flavonolignan-Like Dimers: Still Few Molecules, but with Attractive Properties.
Romanucci V; Di Fabio G; Zarrelli A
Molecules; 2018 Dec; 24(1):. PubMed ID: 30597952
[TBL] [Abstract][Full Text] [Related]
13. Microbial transformation of silybin by Trichoderma koningii.
Kim HJ; Park HS; Lee IS
Bioorg Med Chem Lett; 2006 Feb; 16(4):790-3. PubMed ID: 16309908
[TBL] [Abstract][Full Text] [Related]
14. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression.
Wu KJ; Zeng J; Zhu GD; Zhang LL; Zhang D; Li L; Fan JH; Wang XY; He DL
Acta Pharmacol Sin; 2009 Aug; 30(8):1162-8. PubMed ID: 19578386
[TBL] [Abstract][Full Text] [Related]
15. The study of flavonolignan association patterns in fruits of diverging Silybum marianum (L.) Gaertn. chemotypes provides new insights into the silymarin biosynthetic pathway.
Martinelli T; Whittaker A; Benedettelli S; Carboni A; Andrzejewska J
Phytochemistry; 2017 Dec; 144():9-18. PubMed ID: 28863306
[TBL] [Abstract][Full Text] [Related]
16. Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.
Lu W; Lin C; King TD; Chen H; Reynolds RC; Li Y
Cell Signal; 2012 Dec; 24(12):2291-6. PubMed ID: 22820499
[TBL] [Abstract][Full Text] [Related]
17. 7-O-aminoalkyl-2,3-dehydrosilibinins: Synthesis and in vitro Anti-cancer Efficacy.
Ma DY; Zhang LC; Peng KJ; Zeng J; Liu LJ; Luo ZY; Liu SY
Anticancer Agents Med Chem; 2018; 18(8):1156-1162. PubMed ID: 29607789
[TBL] [Abstract][Full Text] [Related]
18. Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells.
Tyagi A; Sharma Y; Agarwal C; Agarwal R
Pharm Res; 2008 Sep; 25(9):2143-50. PubMed ID: 18253818
[TBL] [Abstract][Full Text] [Related]
19. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
20. Seleno-aspirin compound AS-10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells.
Karelia DN; Kim S; Plano D; Sharma AK; Jiang C; Lu J
Prostate; 2023 Jan; 83(1):16-29. PubMed ID: 35996318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
